Novo Nordisk

Profile narrative

Novo Nordisk is a Danish multinational pharmaceutical company focused on the discovery, development and manufacturing of medicines for chronic diseases. Its core therapeutic areas include diabetes care, obesity treatment, hemophilia, growth disorders and hormone replacement therapy. The company is known for producing insulin formulations and GLP‑1 receptor agonist medications such as semaglutide. Novo Nordisk supplies its medicines and related delivery devices to patients and healthcare providers in numerous countries worldwide. It invests heavily in research and development to advance biologics and innovative drug delivery technologies.

Its headquarters are situated in Bagsværd, Denmark, which serves as the central hub for global operations. Novo Nordisk conducts research and development activities across multiple sites in Europe, North America and Asia. It maintains a network of subsidiaries and manufacturing plants that support production and distribution of its products. The company is publicly traded, with shares listed on the NASDAQ and the Copenhagen Stock Exchange. Its operations span the entire value chain from early‑stage research to commercialization and post‑marketing surveillance.

Novo Nordisk distinguishes itself through a strong emphasis on biologics and innovative drug delivery technologies. The firm has been a leader in advancing GLP‑1 based therapies, which are central to modern diabetes and obesity management. In addition to pharmaceuticals, Novo Nordisk invests in digital health tools and artificial intelligence to support drug discovery and clinical trial processes. Its commitment to scientific rigor is reflected in extensive clinical trial programs that generate data used for regulatory submissions. The recent cyber incidents described in the source material underscore the importance the company places on protecting sensitive clinical trial and research data.

Incidents

2 incidents linked to this organisation.